David John Meloni

Title: David John Meloni: Innovator in Pharmaceutical Chemistry

Introduction

David John Meloni is a notable inventor based in Newark, DE (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds that target platelet aggregation.

Latest Patents

One of his key patents is for Crystalline Roxifiban, a potent platelet glycoprotein IIb/IIIa antagonist. This invention describes the production of roxifiban in crystalline form, which exists in two polymorphic forms, designated Form 1 and Form 2. These forms are characterized by x-ray powder diffraction and solid-state carbon NMR. The patent also outlines pharmaceutical compositions and methods for the treatment or prevention of diseases mediated by platelet aggregation.

Career Highlights

David John Meloni is associated with DuPont Pharmaceuticals Company, where he has been instrumental in advancing pharmaceutical research and development. His work has contributed to the understanding and treatment of conditions related to platelet aggregation.

Collaborations

Throughout his career, Meloni has collaborated with esteemed colleagues, including Michael B Maurin and Philip Ma. These partnerships have fostered innovation and enhanced the impact of their collective research efforts.

Conclusion

David John Meloni's contributions to pharmaceutical chemistry, particularly through his patent for Crystalline Roxifiban, highlight his role as an innovator in the field. His work continues to influence the development of treatments for diseases related to platelet aggregation.